Preferred Label : enfortumab vedotin;
MeSH hyponym : AGS-22CE; AGS-22ME; AGS-22M6E;
UNII : DLE8519RWM;
Origin ID : C000632577;
UMLS CUI : C4519740;
- ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://ansm.sante.fr/tableau-acces-derogatoire/enfortumab-vedotin-padcev
2024
false
false
false
France
French
drug information
insurance, health, reimbursement
enfortumab vedotin
enfortumab vedotin
Locally Advanced Urothelial Carcinoma
carcinoma, transitional cell
urologic neoplasms
Metastatic Urothelial Carcinoma
neoplasm metastasis
Refractory Urothelial Carcinoma
infusions, intravenous
antineoplastic agents
antineoplastic combined chemotherapy protocols
pembrolizumab
Enfortumab Vedotin/Pembrolizumab Regimen
Unresectable Urothelial Carcinoma
---
https://www.has-sante.fr/jcms/p_3546650/fr/padcev-enfortumab-vedotin-carcinome-urothelial
2024
false
false
false
France
Enfortumab Vedotin/Pembrolizumab Regimen
treatment outcome
insurance, health, reimbursement
urologic neoplasms
antineoplastic combined chemotherapy protocols
pembrolizumab
Metastatic Urothelial Carcinoma
Unresectable Urothelial Carcinoma
adult
enfortumab vedotin
antineoplastic agents
evaluation of the transparency committee
carcinoma
enfortumab vedotin
---
https://www.has-sante.fr/jcms/p_3477569/fr/padcev-enfortumab-vedotin-carcinome-urothelial
2023
France
evaluation of the transparency committee
enfortumab vedotin
enfortumab vedotin
carcinoma
Urothelial Carcinoma
Enfortumab Vedotin
---
https://www.has-sante.fr/jcms/p_3395521/fr/padcev-enfortumab-vedotin-carcinome-urothelial
2022
France
evaluation of the transparency committee
enfortumab vedotin
enfortumab vedotin
---
https://www.has-sante.fr/jcms/p_3396009/fr/padcev-enfortumab-vedotine-cancer-urothelial
2022
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
infusions, intravenous
antineoplastic agents
enfortumab vedotin
enfortumab vedotin
adult
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Refractory Urothelial Carcinoma
---
https://ansm.sante.fr/actualites/cancer-de-la-vessie-des-mesures-pour-reduire-le-risque-de-graves-reactions-cutanees-associe-a-lenfortumab-vedotin-autorise-en-acces-precoce
2022
false
false
false
France
French
urinary bladder neoplasms
enfortumab vedotin
Metastatic Bladder Urothelial Carcinoma
Locally Advanced Bladder Urothelial Carcinoma
patients guideline
continuity of patient care
drug eruptions
stevens-johnson syndrome
epidermal necrolysis, toxic
pharmacovigilance note
drug monitoring
enfortumab vedotin
---
https://www.has-sante.fr/jcms/p_3345527/fr/padcev-enfortumab-vedotin-carcinome-urothelial
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
enfortumab vedotin
Advanced Urothelial Carcinoma
urologic neoplasms
carcinoma
Metastatic Urothelial Carcinoma
enfortumab vedotin
package leaflet
summary of product characteristics
infusions, intravenous
urothelium
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
adult
evaluation of the transparency committee
enfortumab vedotin
---
https://ansm.sante.fr/informations-de-securite/acces-compassionnel-a-enfortumab-vedotin-maintien-de-la-suspension-et-recommandations-sur-la-prise-en-charge-des-toxicites-cutanees
2022
false
false
false
France
French
pharmacovigilance note
drug eruptions
stevens-johnson syndrome
epidermal necrolysis, toxic
package leaflet
practice guideline
continuity of patient care
infusions, intravenous
enfortumab vedotin
enfortumab vedotin
---
https://www.ema.europa.eu/en/medicines/human/EPAR/padcev
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
enfortumab vedotin
enfortumab vedotin
enfortumab vedotin
drug approval
europe
antineoplastic agents
antineoplastic agents
adult
urogenital neoplasms
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Refractory Urothelial Carcinoma
infusions, intravenous
aged
pregnancy
breast feeding
product surveillance, postmarketing
drug interactions
neoplasm metastasis
drug evaluation, preclinical
---
https://cadth.ca/fr/enfortumab-vedotine
2021
false
false
false
Canada
French
English
enfortumab vedotin
drug information
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
enfortumab vedotin
antibodies, monoclonal
---